https://www.selleckchem.com/pr....oducts/sodium-ascorb
Results showed that a) reappraisal use was associated with both subsequent depressive symptoms and trajectories of depressive symptoms over time, b) these associations were moderated by perceptions of regulatory success. Higher levels of reappraisal use were associated with lower levels of depressive symptoms only for those who reported higher than average between-subject regulatory success when reappraisal was enacted.The development of anti-COVID-19 drugs has become the top priority since the outbreak of the epidemic, and Tra
Like
Comment
Share
